[Seite 50↓]

Literatur

  1. Aiello (1995 ): Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci 1995, 92 (23), S.10457-10461

  2. Altwein (1997 ): Altwein F: Altersabhängige Referenzbereiche im Kindes- und Jugendalter für IGF-1, IGFBP-3 und IGFBP-1 und Methodenvergleich für die IGF-1 und IGFBP-3-Bestimmungen mittels der IRMA- und ELISA-Technik. Inaugural-Dissertation, Berlin, 1997

  3. Arteaga (1989 ): Arteaga CL, Kitten L, Coronado EB, Jacobs S, Kull FC Jr., Allred DC, Osborne CK: Blockade of the type 1 somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989, 84 (5), S.1418-1423

  4. Baumann (1992 ): Baumann TM: Aspekte der Früherkennungsuntersuchungen beim Mammakarzinom. Inaugural-Dissertation, Tübingen, 1992

  5. Becker (200 1): Becker N: Entwicklung der Inzidenz und Mortalität an Brustkrebs. Der Radiologe 2001, 41, S.337-343

  6. Bohlke (1998 ): Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS: Insulin-like growth factor-1 in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998, 9, S. 570-573

  7. Brown (1995 ): Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ : Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathol 1995, 26 (1), S.86-91

  8. Bruning (1995): Bruning PF, Van Doorn J, Bonfrér JMG, Van Noord PAH, Korse CM, Linders C, Hart AAM: Insulin-like growth-factor-binding protein 3 is decreases in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995, 62, 266-270

  9. Bruns (1994 ): Bruns A: Veränderungen im endokrinen System bei postmenopausalen Frauen mit metastasiertem Mammakarzinom unter einer Behandlung mit Tamoxifen bzw. Toremifene. Inaugural-Dissertation, Bonn, 1994

  10. Chang-Claude (1994 ): Chang-Claude J, Eby N, Becher H: Die Bedeutung genetischer Faktoren für die Entstehung von Brustkrebs. Zentralblatt für Gynäkologie 1994, 116, S.660-669

  11. Chang-Claude (1995 ): Chang-Claude J, Becher H, Hamann U, Schroeder-Kurth T: Risikoabschätzung für das familiäre Auftreten von Brustkrebs. Zentralblatt für Gynäkologie 1995, 117, S.423-434

  12. Claffey (1995 ): Claffey KP, Senger DR, Spiegelman BM: Structural requirements for dimerization, glycosylation, secretion and biological function of VPF/ VEGF. Biochem Biophys Acta 1995, 1246 (1), S.1-9


  13. [Seite 51↓]

    Claffey (1996 ): Claffey KP, Robinson GS: Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996, 15 (2), S. 165-176

  14. Claus (1994) : Claus EB, Risch NJ, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994, 73 (3), S.643-651

  15. Delozier (1986 ): Delozier T, Julien JP, Juret P: Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial . Breast Cancer Res Treat 1986, 7, S.105-110

  16. Dirix (1996 ): Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C, van Oosterom AT: Serum basic fibroblast growth factor and vascular endothelial growth factor and tumor growth kinetic in advanced colorectal cancer. Ann Oncol 1996, 7, S.843-848

  17. Dubois (1995 ): Dubois V, Coussi D, Schonne E, Remacle C, Trouet A: Intracellular lebels and secretion of insulin-like growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells . Eur J Biochem 1995 , 232 , 47-53

  18. Dvorak (1991 ): Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, van de Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor ) in tumors: Concentration in tumor blood vessels. J Exp Med 1991, 174, S.1275-1278

  19. Early Breast Cancer Trialists Collaborative Group (1992 ): Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992, 339, S.1-15,71-85

  20. Easton (1995 ): Easton DF, Ford D, Bishop DT and the Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA 1-mutation carriers. Am J Hum Genet 1995, 56, S.265-271

  21. Ellis (1998 ): Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, Siddle K, Harris A: Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 1998, 52, S.175-184

  22. Ernhardt (1999) : Ernhardt B, Blohmer JU, Schuerenkaemper P, Lichtenegger W: Correlation of vascular endothelial growth factor with pathohistological parameters in breast tumors, preliminary results 1999

  23. Fiedler (2001 ): Fiedler W, Gehling U, Mende T, Hossfeld DK: Neoangiogenese und Tumorwachstum, Pathophysiologie und neue therapeutische Ansätze. Deutsches Ärzteblatt 2001, Jg.98, 21, S.1392-1394

  24. Fisher (1986 ): Fisher B, Redmond C, Brown A: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the national Surgical Breast and Bowel Profect trial. J Clin Oncol 1986, 4, S.459-471

  25. Folkman und Shing (1992 ): Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992, 267(16), S.10931-10934

  26. Folkman (1992 ): Folkman J: The role of angiogenesis in tumor growth. Semin cancer Biol 1992, 3 (2), S. 65-71

  27. Folkman (1994 ): Folkman J: Angiogenesis and breast cancer. J Clin Oncol 1994, 12/3, S.441-443


  28. [Seite 52↓]

    Folkman (1995 ): Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995, 1, S.27-31

  29. Folkman (1996 ): Folkman J Fighting cancer by attacking its blood supply. Scientific American 1996, S. 116-119

  30. Franceschi (1998 ): Franceschi S, Levi F, La Vecchia C, Randimbiso L, Te VC: Second cancers following in situ carcinoma of the breast. Int J Cancer 1998, 77, S.392-395

  31. Frankel (1998 ): Frankel S, Gunnell DJ, Peters TJ, Maynard M, Davey-Smith G: Childhood energy intake and adult mortality from cancer: The Boyd Orr cohort study. BMJ 1998, 316 (7130), S.499-504

  32. Friedl (1993) : Friedl A, Jordan VC, Pollak M: Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993, 29A, S.1368-1372

  33. Frykberg (1999 ): Frykberg ER: Lobular Carcinoma in situ of the breast. Breast J 1999, 5, S.296-303

  34. Gail (1989 ): Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81, S.1879-1886

  35. Gasparini (1997 ) : Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki I, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997, 89, S.139-147

  36. Gasparini (1999 ): Gasparini G: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999, 58 (1), S.17-38

  37. Götze F, Blohmer JU (2002): unveröffentlichte Daten im Druck, Promotion Götze F: Angiogenese und Endokrinium - Erstellung von Normwerten des VEGF/s-VEGF-R2 (KDR)-Systems bei Frauen unter Berücksichtigung von Zyklusphasen und Menopausenstatus (medizinische Dissertation)

  38. Goldman (1998 ): Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao XZ, Bett AJ, Huckle WR, Thomas KA, Curiel DT: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc nat Acad Sci 1998, 95, S.8795-8800

  39. Guidi (1997 ): Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997, 80 (10),S. 1945-1953

  40. Guvakova (1997 ): Guvakova MA, Surmacz E: Tamoxifen interferes with the insulin-like growth factor-1 receptor (IGF-1-R) signaling pathway in breast cancer cells. Cancer Res 1997, 57 (13), S.2606-2010

  41. Hampl (1997 ): Hampl M, Chang-Claude J, Schwarz P, Saeger HD, Schackert HK: Molekulargenetik des hereditären Mammakarzinoms. Zentralblatt für Chirurgie 1997, 122, S.67-73


  42. [Seite 53↓]

    Hankinson (1998 ): Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998, 351, S.1393-1396

  43. Harris (1997 ): Harris AL: Antiangiogenesis for cancer therapy. Lancet 1997, 349, S.13-15

  44. Harstrick (2000 ): Harstrick A, Perschl A: Tumorangiogenese -Therapiekonzepte. Onkologe 2000, 6, S.443-449

  45. Heits (1997 ): Heits F, Katschinski DM, Wiedemann GJ, Weiss C, Jelkmann W: Serum vascular endothelial growth factor, a prognostic indicator in sarcoma and carcinoma patients. Int J Oncol 1997, 10, S.333-337

  46. Heits (1998 ): Heits F, Wiedemann GJ, Jelkmann W: Der vaskuläre endotheliale Wachstumsfaktor VEGF stimuliert die Angiogenese im Guten wie im Bösen. Dtsch med Wschr 1998, 123, S.259-265

  47. Herbstritt (1994 ): Herbstritt L: Untersuchungen zur Bedeutung des EGF-Rezeptor/TGFa-Systems und von VEGF für Proliferation und Angiogenese humaner Tumoren. Inaugural-Dissertation, Freiburg, 1994

  48. Houck (1991 ): Houck KA, Ferrara N, Winer J, Chachianes G, Li B, Leung DW: The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991, 5 (12), S.1806-1814

  49. Huynh (1996 ): Huynh HT, Nickerson T, Pollak M, Yang XF: Regulation of insulin-like growth factor-1 receptor gene expression by the pure antioestrogen ICI 182780. Clin Cancer Res 1996, 2, S.2037-2042

  50. Hyder (1998 ): Hyder SM, Murthy L, Stancel GM: Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998, 58, S. 392-395

  51. Janssen (1999 ): Janssen JAMJL, Lamberts SWJ: Is the measurement of free IGF-1 more indicative than that of total IGF-1 in the evaluation of the biological activity of the GH/IGF-1 axis? J Endocrinol Invest 1999, 22, S.313-315

  52. Jones (1995): Jones JI, Doerr ME, Clemmons DR: Cell Migration: Interactions among integrins, IGFs and IGFBPs. Progress in Growth Factor Res 1995, vol . 6 , Nos.2-4, 319-327

  53. Juul (1994 [a]): Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor-1 in 1030 healthy children, adolescents and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994, 78 (3), S.744-752

  54. Juul (1994 [b ]): Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE: The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, 2, and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol Oxf 1994, 41 (1), S. 85-93


  55. [Seite 54↓]

    Juul (1997 [a]): Juul A, Scheike T, Pedersen AT, Main KM, Anderson AM, Pedersen LM, Skakkebaek NE: Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Human Reproduction 1997, 12, S.2123-2128

  56. Juul (1997 [b ]): Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, Rasmussen S, Muller J, Skakkebaek NE: Free Insulin-like growth factor-1 serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspectes of growth hormone deficiency. J Clin Endocrinol Metab 1997, 82 (8), S. 2497-2502

  57. Kiechle (2001 ): Kiechle M, Schmutzler R: Präventive Strategien bei familiärer Brustkrebsprädisposition. Der Radiologe 2001, 41, S.366-370

  58. Kondo (1993 ): Kondo S, Asano M, Suzuki H: Significance of vascular endothelial growth factor/ vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993, 194 (3), S.1234-1241

  59. Kranz (1999 ): Kranz A, Mattfeld T, Waltenberer J: Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999, 84, S.293-298

  60. Kroll (2000 ): Kroll J, Waltenberger J: Regulation der Endothelfunktion und der Angiogenese durch den vaskulären endothelialen Wachstumsfaktor-A (VEGF-A). Z Kardiol 2000, 89, S.206-218

  61. Langston (1996 ): Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA: BRCA 1 Mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996, 334 (3), S.137-142

  62. Lee (2000 ): Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI: Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen? Int J Oncol 2000, 17, S.149-152

  63. Linderholm (1998 ): Linderholm B, Tavelin B, Grankvist K, Henriksson R: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998, 16 (9), S. 3121-3128

  64. Locopo (1998 ): Lo copo N, Fanelli M, Gasparini G: Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat 1998, 52, S. 159-173

  65. Luo (1998 ): Luo JC, Toyoda M, Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998, 58, S.2594-2600

  66. Malaab (1992 ): Malaab SA, Pollak M, Goodyer CG: Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 1992, 28A (4-5), S.788-793

  67. Marmé (1998 ): Marmé D, Martiny-Baron G, Drevs J, Unger C: Strategien zur Hemmung der Tumorangiogenese am Beispiel des VEGF/VEGF-Rezeptorsystems. Forum DKG. 1998, 13, S. 364-367


  68. [Seite 55↓]

    Marshall (1997 ): Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA: Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997, 6 (5), S.297-301

  69. Martin (1995 ): Martin JL, Coverley JA, Pattison ST, Baxter RC: Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: Stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 1995, 137, S. 1219-1226

  70. McEwen (1979 ): McEwen BS, Davis PG, Parsons B: The brain as a target for steroid hormone action. Ann Rev Neurosci 1979, 2, S.65-112

  71. Melnyk (1996 ): Melnyk O, Shuman MA, Kim KJ: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996, 56, S.921-924

  72. Michels (1996 ): Michels KB, Trichopoulos D, Robins JM, Rosner BA, Manson JE, Hunter DJ, Colditz GA, Hankinson SE, Speizer FE, Willett WC: Birthweight as a risk factor for breast cancer. Lancet 1996, 348 (9041), S.1542-1546

  73. Oh (1998 ): Oh Y: IGF-independent regulation of breast cancer growth. Breast Cancer Res Treat 1998, 47, S. 283-293

  74. Page (1985 ): Page DL, Dupont WD, Rogers LW, Rados MS: Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985, 55 (11), S. 2698-2708

  75. Pekonen (1988 ): Pekonen F, Partanen S, Makinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor-1 and their relation to steroid receptors in human breast cancer. Cancer Res 1988, 48 (5), S.1343-1347

  76. Peyrat (1992 ): Peyrat JP, Bonneterre J: Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat 1992, 22, S. 59-67

  77. Peyrat (1993 ): Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993, 29 A, S. 492-497

  78. Peyrat (1998 ): Peyrat JP, Révillion F, Bonneterre J: Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy. British J of cancer 1998, 77, S.1669-1671

  79. Pollak (1989 ): Pollak M, Tremblay G: Immunocytochemical localization of insulin-like growth factor-1 receptors in primary human breast cancers. Breast Cancer Res Treat 1989, 14, S.174

  80. Pollak (1990 ): Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor 1 levels in stage 1 breast cancer patients. J Natl Cancer Inst 1990, 82, S.1693-1697

  81. Pollak (1992 ): Pollak M, Huynh H, Pratt S: Tamoxifen reduces serum insulin-like growth factor 1 (IGF 1). Breast Cancer Res Treat 1992, 22, S.91-100

  82. Pollak (1998 ): Pollak M: IGF-Physiology and breast cancer. Recent Results Cancer Res 1998, 152, S.63-69


  83. [Seite 56↓]

    Pratt (1993 ): Pratt SE, Pollak MN: Estrogen and antiestrogen modulation of MCF-7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993, 53, S. 5193-5198

  84. Pratt und Pollak (1994 ): Pratt SE, Pollak MN: Insulin-like growth factor binding protein 3 (IGFBP-3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994, 198 (1), S. 292-297

  85. Riede (1995 ): Wittekind C, Riede UN: Allgemeine und spezielle Pathologie. 4, Stuttgart, Georg Thieme, 1995, S.954-958

  86. Rohlik (1987 ): Rohlik QT, Adams D, Kull FC Jr.: An antibody to the receptor for insulin-like growth factor-1 inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun 1987, 149, S.276-281

  87. Rosen (1999 ): Rosen CJ: Serum insulin-like growth factors and insulin-like growth factor-binding proteins: Clinical implications. Clinical Chemistry 1999, 48:8(B), S.1384-1390

  88. Salven (1999 ): Salven P, Perhoniemi V, Tykka H, Mäenpää H, Joensuu H: Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 1999, 53, S.161-166

  89. Schmidt-Matthiesen (1982 ): Schmidt-Matthiesen W: Gynäkologie und Geburtshilfe, Stuttgart, New York, Schattauer Verlag, 1982

  90. Seidmann (1986 ): Seidmann H: Breast cancer goes up to 10%. Oncol Times 1986, 8, S.3

  91. Shweiki (1995 ): Shweiki D, Neeman M, Itin A, Kesher E: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci 1995, 92, S.768-772

  92. Sutherland (1980 ): Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM: High-affinity anti-oestrogen binding sites distinct from the oestrogen receptor. Nature 1980, 288, S.273-275

  93. Toi (1994 ): Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85, S.1045-1049

  94. Toi (1996 ): Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996, 77 (6), S. 1101-1106

  95. van Dessel (1996 ): van Dessel T, Chandrasekher Y, Yap OW, Lee PD, Hintz RL, Faessen GH, Braat DD, Fauser BC, Giudice LC: Serum and follicular fluid levels of insulin-like growth factor-1 (IGF-1), IGF-2, and IGF-binding protein-1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab 1996, 81 (3), S.1224-1231

  96. van Doorn (2001 ): van Doorn J: Insulin-like growth factor (IGF) binding proteins in health and disease, with a focus on IGFBP-3. 1. DSL Growth Factor Dialogue, Amersfoort, 19. January 2001


  97. [Seite 57↓]

    Wang (1995 ): Wang HS, Lee JD, Soong YK: Serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 and -3 in women with regular menstrual cycles. Fertil Steril 1995, 63 (6), S.1204-1209

  98. Wärnberg (2000 ): Wärnberg F, Yuen J, Holmberg L: Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 2000, 355, S.724-725

  99. Weidner (199 2): Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 85 (8), S. 674-676

  100. Werner (2000 ): Werner H, Le Roith D: New concepts in regulation and function of the insulin-like growth factor: implications for understanding normal growth and neoplasia. CMLS, Cell Mol Life Sci 2000, 57, S.932-942

  101. Yamamoto (1996) : Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T: Concentrations of vascular endothelial growth factor in sera of normal controls and cancer patients. Clin Cancer Res 1996, 2, S.821-826

  102. Yu (1998) : Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP: Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer (Pred Oncol) 1998, 79 , 624-628

  103. Zaccheo (1986 ): Zaccheo T, Ornati G, di Salle E: Antioestrogenic and antitumor properties of the new triphenylethylene derivate Toremifene in the rat. Int Cancer Congress Budapest, Abstract 2996, 1986

  104. Zapf (1997 ): Zapf J: Total and free IGF serum levels. Eur J Endocrinol 1997, 136, S. 146-147


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
17.02.2004